{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:28:12Z","timestamp":1790674092737,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T00:00:00Z","timestamp":1508716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1038\/onc.2017.391","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T20:04:18Z","timestamp":1508789058000},"page":"897-911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition"],"prefix":"10.1038","volume":"37","author":[{"given":"P","family":"Dietrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kuphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Spruss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Hellerbrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A K","family":"Bosserhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,23]]},"reference":[{"key":"BFonc2017391_CR1","first-page":"120","volume":"810","author":"U Leiter","year":"2014","unstructured":"Leiter U, Eigentler T, Garbe C . Epidemiology of skin cancer. Adv Exp Med Biol 2014; 810: 120\u2013140.","journal-title":"Adv Exp Med Biol"},{"key":"BFonc2017391_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejca.2016.01.011","volume":"60","author":"M Harries","year":"2016","unstructured":"Harries M, Malvehy J, Lebbe C, Heron L, Amelio J, Szabo Z et al. Treatment patterns of advanced malignant melanoma (stage III-IV) - a review of current standards in Europe. Eur J Cancer 2016; 60: 179\u2013189.","journal-title":"Eur J Cancer"},{"issue":"Suppl 7","key":"BFonc2017391_CR3","doi-asserted-by":"publisher","first-page":"vii86","DOI":"10.1093\/annonc\/mds229","volume":"23","author":"R Dummer","year":"2012","unstructured":"Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G . Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl 7): vii86\u2013vii91.","journal-title":"Ann Oncol"},{"key":"BFonc2017391_CR4","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1084\/jem.20152021","volume":"213","author":"AG Chapuis","year":"2016","unstructured":"Chapuis AG, Lee SM, Thompson JA, Roberts IM, Margolin KA, Bhatia S et al. Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J Exp Med 2016; 213: 1133\u20131139.","journal-title":"J Exp Med"},{"key":"BFonc2017391_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1084\/jem.20121439","volume":"210","author":"RN Matin","year":"2013","unstructured":"Matin RN, Chikh A, Chong SL, Mesher D, Graf M, Sanza P et al. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med 2013; 210: 581\u2013603.","journal-title":"J Exp Med"},{"key":"BFonc2017391_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40257-014-0083-7","volume":"15","author":"C Karimkhani","year":"2014","unstructured":"Karimkhani C, Gonzalez R, Dellavalle RP . A review of novel therapies for melanoma. Am J Clin Dermatol 2014; 15: 323\u2013337.","journal-title":"Am J Clin Dermatol"},{"key":"BFonc2017391_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/DHPS.S39568","volume":"6","author":"JJ Luke","year":"2014","unstructured":"Luke JJ, Ott PA . New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf 2014; 6: 77\u201388.","journal-title":"Drug Healthc Patient Saf"},{"key":"BFonc2017391_CR8","first-page":"1507","volume":"5","author":"DJ Monsma","year":"2015","unstructured":"Monsma DJ, Cherba DM, Eugster EE, Dylewski DL, Davidson PT, Peterson CA et al. Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms. Am J Cancer Res 2015; 5: 1507\u20131518.","journal-title":"Am J Cancer Res"},{"key":"BFonc2017391_CR9","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.3392","volume":"19","author":"P Lito","year":"2013","unstructured":"Lito P, Rosen N, Solit DB . Tumor adaptation and resistance to RAF inhibitors. Nat Med 2013; 19: 1401\u20131409.","journal-title":"Nat Med"},{"key":"BFonc2017391_CR10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973\u2013977.","journal-title":"Nature"},{"key":"BFonc2017391_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.CD-12-0313","volume":"3","author":"O Maertens","year":"2013","unstructured":"Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 2013; 3: 338\u2013349.","journal-title":"Cancer Discov"},{"key":"BFonc2017391_CR12","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-14-2662","volume":"21","author":"F McCormick","year":"2015","unstructured":"McCormick F . KRAS as a therapeutic target. Clin Cancer Res 2015; 21: 1797\u20131801.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017391_CR13","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1158\/1078-0432.CCR-14-3214","volume":"21","author":"AD Cox","year":"2015","unstructured":"Cox AD, Der CJ, Philips MR . Targeting RAS membrane association: back to the future for anti-RAS drug discovery? Clin Cancer Res 2015; 21: 1819\u20131827.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017391_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","volume":"25","author":"AG Stephen","year":"2014","unstructured":"Stephen AG, Esposito D, Bagni RK, McCormick F . Dragging Ras back in the ring. Cancer Cell 2014; 25: 272\u2013281.","journal-title":"Cancer Cell"},{"key":"BFonc2017391_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cell.2014.02.051","volume":"157","author":"M Schmick","year":"2014","unstructured":"Schmick M, Vartak N, Papke B, Kovacevic M, Truxius DC, Rossmannek L et al. KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport. Cell 2014; 157: 459\u2013471.","journal-title":"Cell"},{"key":"BFonc2017391_CR16","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nature12205","volume":"497","author":"G Zimmermann","year":"2013","unstructured":"Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M et al. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 2013; 497: 638\u2013642.","journal-title":"Nature"},{"key":"BFonc2017391_CR17","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1158\/2159-8290.CD-13-0900","volume":"4","author":"TL Yuan","year":"2014","unstructured":"Yuan TL, Fellmann C, Lee CS, Ritchie CD, Thapar V, Lee LC et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov 2014; 4: 1182\u20131197.","journal-title":"Cancer Discov"},{"key":"BFonc2017391_CR18","doi-asserted-by":"publisher","first-page":"E3553","DOI":"10.1073\/pnas.1412686111","volume":"111","author":"W Xue","year":"2014","unstructured":"Xue W, Dahlman JE, Tammela T, Khan OF, Sood S, Dave A et al. Small RNA combination therapy for lung cancer. Proc Natl Acad Sci USA 2014; 111: E3553\u2013E3561.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017391_CR19","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/jid.2015.198","volume":"135","author":"C Posch","year":"2015","unstructured":"Posch C, Cholewa BD, Vujic I, Sanlorenzo M, Ma J, Kim ST et al. Combined inhibition of MEK and Plk1 has synergistic antitumor activity in NRAS mutant melanoma. J Invest Dermatol 2015; 135: 2475\u20132483.","journal-title":"J Invest Dermatol"},{"key":"BFonc2017391_CR20","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-09-4254","volume":"70","author":"C Milagre","year":"2010","unstructured":"Milagre C, Dhomen N, Geyer FC, Hayward R, Lambros M, Reis-Filho JS et al. A mouse model of melanoma driven by oncogenic KRAS. Cancer Res 2010; 70: 5549\u20135557.","journal-title":"Cancer Res"},{"key":"BFonc2017391_CR21","doi-asserted-by":"publisher","first-page":"8048","DOI":"10.1200\/JCO.2005.02.0735","volume":"23","author":"PA Gimotty","year":"2005","unstructured":"Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 2005; 23: 8048\u20138056.","journal-title":"J Clin Oncol"},{"key":"BFonc2017391_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2559.2005.02193.x","volume":"47","author":"I Depasquale","year":"2005","unstructured":"Depasquale I, Thompson WD . Microvessel density for melanoma prognosis. Histopathology 2005; 47: 186\u2013194.","journal-title":"Histopathology"},{"key":"BFonc2017391_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","volume":"18","author":"J Villanueva","year":"2010","unstructured":"Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K. Cancer Cell 2010; 18: 683\u2013695.","journal-title":"Cancer Cell"},{"key":"BFonc2017391_CR24","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.celrep.2013.08.023","volume":"4","author":"J Villanueva","year":"2013","unstructured":"Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep 2013; 4: 1090\u20131099.","journal-title":"Cell Rep"},{"key":"BFonc2017391_CR25","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jamaoncol.2015.0565","volume":"1","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Sosman JA . Therapeutic advances and treatment options in metastatic melanoma. JAMA Oncol 2015; 1: 380\u2013386.","journal-title":"JAMA Oncol"},{"key":"BFonc2017391_CR26","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1002\/cncr.28864","volume":"120","author":"M Burotto","year":"2014","unstructured":"Burotto M, Chiou VL, Lee JM, Kohn EC . The MAPK pathway across different malignancies: a new perspective. Cancer 2014; 120: 3446\u20133456.","journal-title":"Cancer"},{"key":"BFonc2017391_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1479-5876-8-39","volume":"8","author":"JN Sondergaard","year":"2010","unstructured":"Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010; 8: 39.","journal-title":"J Transl Med"},{"key":"BFonc2017391_CR28","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/jid.2014.418","volume":"135","author":"J Wang","year":"2015","unstructured":"Wang J, Huang SK, Marzese DM, Hsu SC, Kawas NP, Chong KK et al. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol 2015; 135: 532\u2013541.","journal-title":"J Invest Dermatol"},{"key":"BFonc2017391_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11523-014-0318-9","volume":"10","author":"A Gross","year":"2015","unstructured":"Gross A, Niemetz-Rahn A, Nonnenmacher A, Tucholski J, Keilholz U, Fusi A . Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway. Target Oncol 2015; 10: 77\u201384.","journal-title":"Target Oncol"},{"key":"BFonc2017391_CR30","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1111\/bph.12220","volume":"169","author":"MJ Sale","year":"2013","unstructured":"Sale MJ, Cook SJ . That which does not kill me makes me stronger; combining ERK1\/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. Br J Pharmacol 2013; 169: 1708\u20131722.","journal-title":"Br J Pharmacol"},{"key":"BFonc2017391_CR31","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1128\/MCB.16.10.5546","volume":"16","author":"BE Wilson","year":"1996","unstructured":"Wilson BE, Mochon E, Boxer LM . Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 1996; 16: 5546\u20135556.","journal-title":"Mol Cell Biol"},{"key":"BFonc2017391_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0","volume":"79","author":"MJ Boucher","year":"2000","unstructured":"Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N . MEK\/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000; 79: 355\u2013369.","journal-title":"J Cell Biochem"},{"key":"BFonc2017391_CR33","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.bbrc.2015.06.032","volume":"463","author":"J Yang","year":"2015","unstructured":"Yang J, Song Q, Cai Y, Wang P, Wang M, Zhang D . RLIP76-dependent suppression of PI3K\/AKT\/Bcl-2 pathway by miR-101 induces apoptosis in prostate cancer. Biochem Biophys Res Commun 2015; 463: 900\u2013906.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2017391_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ccr.2014.01.005","volume":"25","author":"E Grabocka","year":"2014","unstructured":"Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L et al. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 2014; 25: 243\u2013256.","journal-title":"Cancer Cell"},{"key":"BFonc2017391_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761\u2013774.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2017391_CR36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nature10937","volume":"483","author":"Z Chen","year":"2012","unstructured":"Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483: 613\u2013617.","journal-title":"Nature"},{"key":"BFonc2017391_CR37","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ncomms2173","volume":"3","author":"HH Jeng","year":"2012","unstructured":"Jeng HH, Taylor LJ, Bar-Sagi D . Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat Commun 2012; 3: 1168.","journal-title":"Nat Commun"},{"key":"BFonc2017391_CR38","doi-asserted-by":"publisher","first-page":"016008","DOI":"10.1088\/1478-3975\/12\/1\/016008","volume":"12","author":"C Ruiz","year":"2015","unstructured":"Ruiz C, Li J, Luttgen MS, Kolatkar A, Kendall JT, Flores E et al. Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Phys Biol 2015; 12: 016008.","journal-title":"Phys Biol"},{"key":"BFonc2017391_CR39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1158\/1078-0432.CCR-15-1162","volume":"22","author":"MA Wilson","year":"2015","unstructured":"Wilson MA, Zhao F, Khare S, D'Andrea K, Wubbenhorst B, Roszik J et al. Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma. Clin Cancer Res 2015; 22: 374\u2013382.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017391_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fonc.2015.00135","volume":"5","author":"M Sweetlove","year":"2015","unstructured":"Sweetlove M, Wrightson E, Kolekar S, Rewcastle GW, Baguley BC, Shepherd PR et al. Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth. Front Oncol 2015; 5: 135.","journal-title":"Front Oncol"},{"key":"BFonc2017391_CR41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrm3979","volume":"16","author":"H Lavoie","year":"2015","unstructured":"Lavoie H, Therrien M . Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol 2015; 16: 281\u2013298.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFonc2017391_CR42","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ccell.2015.07.001","volume":"28","author":"A Herrero","year":"2015","unstructured":"Herrero A, Pinto A, Colon-Bolea P, Casar B, Jones M, Agudo-Ibanez L et al. Small molecule inhibition of ERK dimerization prevents tumorigenesis by RAS-ERK pathway oncogenes. Cancer Cell 2015; 28: 170\u2013182.","journal-title":"Cancer Cell"},{"key":"BFonc2017391_CR43","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1517\/14656566.2015.1044971","volume":"16","author":"J Richman","year":"2015","unstructured":"Richman J, Martin-Liberal J, Diem S, Larkin J . BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Expert Opin Pharmacother 2015; 16: 1285\u20131297.","journal-title":"Expert Opin Pharmacother"},{"key":"BFonc2017391_CR44","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ctrv.2015.04.010","volume":"41","author":"P Queirolo","year":"2015","unstructured":"Queirolo P, Picasso V, Spagnolo F . Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treat Rev 2015; 41: 519\u2013526.","journal-title":"Cancer Treat Rev"},{"key":"BFonc2017391_CR45","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1158\/1535-7163.MCT-15-0136-T","volume":"14","author":"SR Whittaker","year":"2015","unstructured":"Whittaker SR, Cowley GS, Wagner S, Luo F, Root DE, Garraway LA . Combined pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors. Mol Cancer Ther 2015; 14: 2700\u20132711.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2017391_CR46","doi-asserted-by":"publisher","first-page":"E536","DOI":"10.1073\/pnas.1418163112","volume":"112","author":"D Perna","year":"2015","unstructured":"Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F et al. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc Natl Acad Sci USA 2015; 112: E536\u2013E545.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017391_CR47","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","volume":"4","author":"H Shi","year":"2014","unstructured":"Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014; 4: 80\u201393.","journal-title":"Cancer Discov"},{"key":"BFonc2017391_CR48","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","volume":"162","author":"W Hugo","year":"2015","unstructured":"Hugo W, Shi H, Sun L, Piva M, Song C, Kong X et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 2015; 162: 1271\u20131285.","journal-title":"Cell"},{"key":"BFonc2017391_CR49","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1158\/1535-7163.MCT-14-0452","volume":"13","author":"T Smyth","year":"2014","unstructured":"Smyth T, Paraiso KH, Hearn K, Rodriguez-Lopez AM, Munck JM, Haarberg HE et al. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther 2014; 13: 2793\u20132804.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2017391_CR50","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1200\/JCO.2013.51.5783","volume":"33","author":"MS Carlino","year":"2015","unstructured":"Carlino MS, Kwan V, Miller DK, Saunders CA, Yip D, Nagrial AM et al. New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. J Clin Oncol 2015; 33: e52\u2013e56.","journal-title":"J Clin Oncol"},{"key":"BFonc2017391_CR51","doi-asserted-by":"crossref","unstructured":"The KRAS-PDEdelta interaction is a therapeutic target. Cancer Discov 2013; 3: OF20.","DOI":"10.1158\/2159-8290.CD-RW2013-116"},{"key":"BFonc2017391_CR52","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1021\/cb500555h","volume":"9","author":"LG Milroy","year":"2014","unstructured":"Milroy LG, Ottmann C . The renaissance of Ras. ACS Chem Biol 2014; 9: 2447\u20132458.","journal-title":"ACS Chem Biol"},{"key":"BFonc2017391_CR53","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/520278a","volume":"520","author":"H Ledford","year":"2015","unstructured":"Ledford H . Cancer: the Ras renaissance. Nature 2015; 520: 278\u2013280.","journal-title":"Nature"},{"key":"BFonc2017391_CR54","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1158\/1078-0432.CCR-15-1125","volume":"22","author":"S Loi","year":"2015","unstructured":"Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P et al. RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1\/PD-L1 immune checkpoint inhibitors. Clin Cancer Res 2015; 22: 1499\u20131509.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017391_CR55","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1084\/jem.20130590","volume":"211","author":"X Fan","year":"2014","unstructured":"Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP . Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 2014; 211: 715\u2013725.","journal-title":"J Exp Med"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/onc2017391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2017391","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/onc.2017.391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/onc2017391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:02:33Z","timestamp":1684472553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2017391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,23]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["BFonc2017391"],"URL":"https:\/\/doi.org\/10.1038\/onc.2017.391","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,23]]},"assertion":[{"value":"17 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}